Trial Profile
Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis in patients with moderate to advanced Fuchs endothelial corneal dystrophy (FECD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ripasudil (Primary)
- Indications Hereditary corneal dystrophies
- Focus Adverse reactions
- 29 Jan 2018 New trial record